Open AccessA multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety
Author(s) -
Ulysse Gaspard,
Mélanie Taziaux,
Marie Mawet,
Maud Jost,
Valérie Gordenne,
Herjan J.T. Coelingh Bennink,
Rogerio A. Løbo,
Wulf H. Utian,
JeanMichel Foidart
Publication year - 2020
Publication title -
menopause
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.086
H-Index - 103
eISSN - 1530-0374
pISSN - 1072-3714
DOI - 10.1097/gme.0000000000001561
Subject(s) - medicine , vasomotor , placebo , adverse effect , progestin , randomized controlled trial , endometrial hyperplasia , urology , endometrium , estrogen , alternative medicine , pathology
The aim of this study was to select the minimum effective dose of estetrol (E4) for the treatment of vasomotor symptoms in postmenopausal women.